FBLG: Wutah bathi EPS kuartalan fibrobiologics.com

Supply chain optimization for bio-raw materials ensures the margins of FibroBiologics, Inc. (FBLG), although profitability relies on insurance reimbursements for the treatment of sclerosis and joints. A shift in the quarterly EPS level allows for an assessment of this balance, where 72.80 indicates the current profit level. This trend is supported by a breakthrough R&D pipeline in cartilage regeneration and the development of innovative cell therapy methods.

FibroBiologics (FBLG) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan saka 21.02.2024 nganti 15.11.2026

Rincian analitis perusahaan FibroBiologics, Inc.

- rega saham lan prakiraan rega para ahli:

Rega saham FibroBiologics|FBLG - Bagan tingkat prakiraan

- informasi kapitalisasi pasar:

Kapitalisasi pasar FibroBiologics Inc.|FBLG - Rega Tumbas Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham FibroBiologics|FBLG - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku fibrobiologics.com|FBLG - Nilai Agregat Aset

- data tingkat utang lan likuiditas finansial:

Utang marang Ekuitas FibroBiologics, Inc.|FBLG - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal FibroBiologics Inc.|FBLG - Utang perusahaan|Utang-utang marang kapitalisasi buku FibroBiologics Inc.|FBLG - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan FibroBiologics|Likuiditas cepet fibrobiologics.com

- indikator bathi lan kelipatan valuasi:

FBLG - Bathi resik perusahaan|Bathi sing dikarepake FibroBiologics, Inc.|FBLG - Kapitalisasi marang bathi|Pangali Forward P/E FibroBiologics Inc.|FBLG - Rasio rega marang wutah bathi resik|Pangali EV/EBITDA FibroBiologics Inc.|FBLG - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) FibroBiologics|FBLG - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan fibrobiologics.com|FBLG - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep FibroBiologics, Inc.

- informasi babagan volume dodolan lan pendapatan:

FBLG - Pendapatan dodolan perusahaan|Prakiraan volume dodolan FibroBiologics, Inc.|FBLG - Koefisien rega marang pendapatan|Rasio rega marang prakiraan pendapatan FibroBiologics Inc.|FBLG - Wutah dodolan YoY sajrone 12 wulan kepungkur

Pambiji fundamental:FibroBiologics - FBLG

Produk asil prodhuksi FibroBiologics, Inc.

The development of regenerative platforms and the monetization of patents by FibroBiologics, Inc. (FBLG) directly impact net income available to shareholders. The current quarterly EPS growth value represents a daily interpolation of earnings per share growth, eliminating time gaps between reports to provide an objective assessment of operating returns and prevent overpaying for the asset when analyzing fundamental indicators.

Pesaing FibroBiologics, Inc. (FBLG)

Mesoblast Pharma (MESO) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|LCTX (Lineage Bio) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan SRZN|CCEL: Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Longeveron Corp (LGVN)|BRTX - Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan CELZ (Creative Medical Technology Holdings, Inc.)